simtuzumab

Simtuzumab is a humanized monoclonal antibody developed for the treatment of fibrotic diseases and certain cancers. It specifically targets lysyl oxidase-like 2 (LOXL2), an enzyme involved in the cross-linking of collagen and elastin, which is critical for connective tissue biogenesis and fibrosis progression. By inhibiting LOXL2, simtuzumab was intended to reduce or reverse fibrosis in conditions such as idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis, liver cirrhosis, myelofibrosis, pancreatic cancer, colorectal cancer, and hepatic fibrosis. Despite its promising mechanism of action as an antifibrotic agent and immunomodulator, clinical trials failed to demonstrate efficacy across multiple indications. As a result, development has been discontinued for all known indications[1][3][4][5][6].

Other names

simtuzumabanti-LOXL2 monoclonal antibodyanti-LOXL-2 monoclonal antibodyanti-LOXL 2 monoclonal antibodyrecombinant humanized anti-LOXL2 monoclonal antibody